CAMP4 Therapeutics Corporation
NASDAQ:CAMPBiotechnology
+$0.10 today
- Market cap
- $257.29M
- Beta
- 0.08
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.49
Volume 0.19M
Average 0.10M
CAMP Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
CAMP4 Therapeutics CorporationNASDAQ: CAMP
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 101.1% from a year ago
Cash & equivalents stood at $99.21M at the end of Q1 FY2026, up 101.1% from a year earlier and down 9.4% from the prior quarter.
Context
- Cash & equivalents amounted to 94.1% of total assets at the end of Q1 FY2026, up 15.5 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +101.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 109.52M USD
- Year-over-year change
- +71.0%
- 4-year CAGR
- +4.7%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 109.52M | +71.0% |
| FY2024 | 2024-12-31 | 64.04M | +66.9% |
| FY2023 | 2023-12-31 | 38.38M | -53.9% |
| FY2022 | 2023-02-28 | 83.19M | -8.7% |
| FY2021 | 2022-02-28 | 91.11M | — |
Cash & Equivalents vs competitors
How CAMP compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +101.1% is the highest of 9, against a peer median of +17.2%.
- Cash & equivalents amounts to 94.1% of total assets for CAMP, versus a peer median of 36.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $99.21M USD | +101.1% | — | 94.1% | |
| Mar 2026 | $50.75M USD | +76.8% | +6.9% | 28.2% | |
| Mar 2026 | $44.69M USD | +24.6% | -20.7% | 96.4% | |
| Mar 2026 | $39.13M USD | -23.8% | -29.5% | 40.5% | |
| Mar 2026 | $37.37M USD | +89.0% | +300.4% | 58.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $34.06M USD | -13.0% | +12.0% | 31.6% |
| Mar 2026 | $32.28M USD | +56.6% | -30.5% | 18.1% | |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$14.18M CAD | +9.8% | -29.1% | 61.2% |
| Mar 2026 | $10.01M USD | -3.4% | +2.5% | 12.6% | |
| Peer median (excluding CAMP) | — | +17.2% | -9.1% | 36.1% | |
Competitors are the stored peer set for CAMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Feb 2022 | FY2022 Feb 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 91.11M | 83.19M | 38.38M | 64.04M | 109.52M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 58.59M | 678K | 442K | 108K | 155K |
| Inventory | 20.18M | 0 | 0 | 0 | 0 |
| Other Current Assets | 23.71M | 205K | 245K | 211K | 4.42M |
| Total Current Assets | 193.59M | 84.41M | 40.01M | 66.38M | 114.1M |
| Property, Plant & Equipment (Net) | 50.06M | 16.8M | 13.31M | 10.3M | 2.74M |
| Goodwill | 94M | 0 | 0 | 0 | 0 |
| Intangible Assets | 33.01M | 0 | 0 | 0 | 0 |
| Long-term Investments | 24.34M | 0 | 0 | 0 | 894K |
| Tax Assets | 4.23M | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.05M | 1.35M | 1.62M | 1.62M | 83K |
| Total Non-current Assets | 208.7M | 18.14M | 14.93M | 11.92M | 3.71M |
| Total Assets | 402.29M | 102.55M | 54.95M | 78.31M | 117.81M |
| Account Payables | 30.78M | 2.15M | 1.04M | 1.21M | 182K |
| Short-term Debt | 7.74M | 0 | 0 | 0 | 286K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 32.4M | 0 | 0 | 385K | 9.39M |
| Other Current Liabilities | 23.96M | 1.78M | 2.34M | 3.2M | 5.66M |
| Total Current Liabilities | 94.88M | 7.95M | 7.81M | 9.6M | 15.51M |
| Long-term Debt | 201.43M | 0 | 0 | 0 | 1.69M |
| Deferred Tax Liabilities | 208K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 14.49M | 0 | 0 | 0 | 8.11M |
| Other Non-current Liabilities | 11.1M | 162.11M | 162.23M | 2K | 44.79M |
| Total Non-current Liabilities | 227.23M | 172.13M | 170.87M | 5.57M | 54.59M |
| Total Liabilities | 322.11M | 180.08M | 178.68M | 15.16M | 70.1M |
| Common Stock | 359K | 1K | 1K | 2K | 6K |
| Retained Earnings | (156.78M) | (110.67M) | (159.96M) | (211.75M) | (292.16M) |
| Accumulated OCI | (2.44M) | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 239.04M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 80.18M | (77.53M) | (123.73M) | 63.14M | 47.7M |
| Total Debt | 209.17M | 12.4M | 11.69M | 8.65M | 1.97M |
| Net Debt | 118.05M | (70.8M) | (26.69M) | (55.39M) | (107.54M) |
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
Intrinsic Alpha fair value
Locked
Current Price
$4.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.